In an interview with Pharm Exec Associate Editor Don Tracy, Femasys founder and CEO Kathy Lee-Sepsick talks about the results of Femaseed’s pivotal trial, Femblock contraceptives, and how the outcome of the 2024 U.S. presidential election may impact women’s health.
Femasys CEO Discusses FemaSeed Pivotal Trial Results and the History of FemBlock Contraception
Leave a comment
